Sonnet BioTherapeutics Announces $888 Million Crypto Strategy
Deal News | Jul 14, 2025 | Globenewswire
Sonnet BioTherapeutics, a biotechnology firm, has entered into a Business Combination Agreement with Rorschach I LLC to form a new entity named Hyperliquid Strategies Inc. This strategic move, valued at $888 million, is intended to launch a cryptocurrency treasury strategy involving 12.6 million HYPE tokens from the Hyperliquid blockchain. The transaction aims to tap into the growing cryptocurrency market, integrating HYPE tokens into treasury management. Atlas Merchant Capital and Paradigm Operations LP are instrumental in this agreement, with leadership roles designated for Bob Diamond and David Schamis within the new entity. The business combination, expected to close later in 2025, involves raising additional funds through private placements, ensuring ongoing development of Sonnet's biotech assets. The transition emphasizes Sonnet's intent to leverage crypto assets while continuing its biotech operations.
Sectors
- Biotechnology
- Cryptocurrency
- Financial Services
Geography
- United States – Sonnet BioTherapeutics is based in New Jersey, and the proposed business combination involves adherence to U.S. financial regulations.
Industry
- Biotechnology – Sonnet BioTherapeutics is primarily a biotechnology firm focusing on oncology, leveraging their platform for drug innovation.
- Cryptocurrency – The strategic shift towards a cryptocurrency treasury strategy, involving HYPE tokens, highlights the significant focus on the digital asset sector.
- Financial Services – Atlas Merchant Capital's participation and financial advisement illustrate the financial services industry's deep involvement in the transaction.
Financials
- 888 million – Total assumed closing value of the business combination between Sonnet and Rorschach.
- 583 million – Value of HYPE tokens based on spot price before signing the Business Combination Agreement.
- 305 million – Gross cash invested in the combination to acquire more HYPE tokens.
- 5.5 million – Amount raised by Sonnet through private placement to fund corporate purposes and transaction expenses.
- 2.0 million – Principal amount of convertible notes sold by Sonnet to be converted into equity.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Sonnet BioTherapeutics, Inc. | Target Company | Company | Sonnet is an oncology-focused biotechnology company, engaging in innovative drug development. |
| Rorschach I LLC | Bidding Company | Company | A newly-formed entity affiliated with Atlas Merchant Capital and Paradigm to execute this business transformation. |
| Atlas Merchant Capital LLC | Bidder Entity, Financial Advisor | Company | Participating in the deal with a focus on financial services expertise. |
| Paradigm Operations LP | Investor | Company | A crypto investment firm, supporting the transaction to integrate cryptocurrency strategies. |
| Bob Diamond | Chairman of the Board | Person | Chairman of Hyperliquid Strategies Inc, Co-founder and CEO of Atlas. |
| David Schamis | Chief Executive Officer | Person | CEO of Hyperliquid Strategies Inc, Co-founder and CIO of Atlas. |
| Chardan | Sole Placement Agent, Financial Advisor | Company | Acts as the sole placement agent and financial advisor to Rorschach in this transaction. |
| Greenberg Traurig, LLP | Legal Advisor | Company | Legal counsel to Rorschach in the transaction. |
| Lowenstein Sandler LLP | Legal Advisor | Company | Legal counsel to Sonnet in the transaction. |